Treatment of Androgenetic Alopecia in Females, 9 Beam
Launched by LEXINGTON INTERNATIONAL, LLC · Sep 21, 2009
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
This is a randomized double-blind, control device clinical study across 5 sites, evaluating changes in terminal hair count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair).
The trial with 60 female subjects who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Ludwig I-4, II-1, II-2, or frontal, have active hair loss within the last 12 months.
Subjects will use the device on three non-concurring days a week as directed per device for 26 weeks duration.
Initia...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of androgenetic alopecia
- • Fitzpatrick Skin Types I-IV
- • Ludwig I-4, II-1, II-2, or frontal
- • Active hair loss within last 12 months
- Exclusion Criteria:
- • Photosensitivity to laser light
- • Malignancy in the target area
- • Pregnancy
- • Lactating females
About Lexington International, Llc
Lexington International, LLC is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a strong focus on dermatological solutions, the company specializes in the evaluation of novel therapies and medical devices aimed at improving skin health. Lexington International is committed to adhering to the highest standards of regulatory compliance and ethical practices, ensuring the integrity and reliability of its clinical trials. Through strategic collaborations and a patient-centered approach, the organization strives to deliver cutting-edge solutions that enhance quality of life and address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Miami, Florida, United States
Palm Beach, Florida, United States
Hackensack, New Jersey, United States
Lynchburg, Virginia, United States
Patients applied
Trial Officials
Michael Jarratt, M.D.
Principal Investigator
DermaResearch, Inc.
Abe Marcadis, M.D.
Principal Investigator
Palm Beach Research Center
David Goldberg, M.D.
Principal Investigator
Hackensack, NJ
Neil S Sadick, MD
Principal Investigator
Sadick Research Group
Jose Mendez, DO
Principal Investigator
International Dermatology Research, Inc.
Janet Hickman, MD
Principal Investigator
The Education and Researvh Foundation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials